Harshman L - Search Results

1

Continuous daily dosing of sunitinib in patients with metastatic renal cell cancer.

Harshman L, Srinivas S. Harshman L, et al. Onkologie. 2008 Sep;31(8-9):432-3. doi: 10.1159/000144179. Epub 2008 Aug 12. Onkologie. 2008. PMID: 18787349 Free article. No abstract available.

2

Prognostic Value of Quantitative Metabolic Metrics on Baseline Pre-Sunitinib FDG PET/CT in Advanced Renal Cell Carcinoma.

Minamimoto R, Barkhodari A, Harshman L, Srinivas S, Quon A. Minamimoto R, et al. Among authors: harshman l. PLoS One. 2016 Apr 28;11(4):e0153321. doi: 10.1371/journal.pone.0153321. eCollection 2016. PLoS One. 2016. PMID: 27123976 Free PMC article.

3

Current status of cytoreductive nephrectomy in metastatic renal cell carcinoma.

Harshman LC, Srinivas S. Harshman LC, et al. Expert Rev Anticancer Ther. 2007 Dec;7(12):1749-61. doi: 10.1586/14737140.7.12.1749. Expert Rev Anticancer Ther. 2007. PMID: 18062749 Review.

4

The combination of thalidomide and capecitabine in metastatic renal cell carcinoma -- is not the answer.

Harshman LC, Li M, Srinivas S. Harshman LC, et al. Am J Clin Oncol. 2008 Oct;31(5):417-23. doi: 10.1097/COC.0b013e318168ef47. Am J Clin Oncol. 2008. PMID: 18838876 Clinical Trial.

5

Laparoscopic radical nephrectomy after shrinkage of a caval tumor thrombus with sunitinib.

Harshman LC, Srinivas S, Kamaya A, Chung BI. Harshman LC, et al. Nat Rev Urol. 2009 Jun;6(6):338-43. doi: 10.1038/nrurol.2009.84. Nat Rev Urol. 2009. PMID: 19498412

6

Surgical outcomes and complications associated with presurgical tyrosine kinase inhibition for advanced renal cell carcinoma (RCC).

Harshman LC, Yu RJ, Allen GI, Srinivas S, Gill HS, Chung BI. Harshman LC, et al. Urol Oncol. 2013 Apr;31(3):379-85. doi: 10.1016/j.urolonc.2011.01.005. Epub 2011 Feb 25. Urol Oncol. 2013. PMID: 21353796

7

Conditional survival of patients with metastatic renal-cell carcinoma treated with VEGF-targeted therapy: a population-based study.

Harshman LC, Xie W, Bjarnason GA, Knox JJ, MacKenzie M, Wood L, Srinivas S, Vaishampayan UN, Tan MH, Rha SY, Donskov F, Agarwal N, Kollmannsberger C, North S, Rini BI, Heng DY, Choueiri TK. Harshman LC, et al. Lancet Oncol. 2012 Sep;13(9):927-35. doi: 10.1016/S1470-2045(12)70285-1. Epub 2012 Aug 8. Lancet Oncol. 2012. PMID: 22877847 Free PMC article.

8

A phase II study of bevacizumab and everolimus as treatment for refractory metastatic renal cell carcinoma.

Harshman LC, Barbeau S, McMillian A, Srinivas S. Harshman LC, et al. Clin Genitourin Cancer. 2013 Jun;11(2):100-6. doi: 10.1016/j.clgc.2012.12.002. Epub 2013 Jan 24. Clin Genitourin Cancer. 2013. PMID: 23352238 Clinical Trial.

9

First-line Mammalian target of rapamycin inhibition in metastatic renal cell carcinoma: an analysis of practice patterns from the International Metastatic Renal Cell Carcinoma Database Consortium.

Harshman LC, Kroeger N, Rha SY, Donskov F, Wood L, Tantravahi SK, Vaishampayan U, Rini BI, Knox J, North S, Ernst S, Yuasa T, Srinivas S, Pal S, Heng DY, Choueiri TK. Harshman LC, et al. Clin Genitourin Cancer. 2014 Oct;12(5):335-40. doi: 10.1016/j.clgc.2014.03.003. Epub 2014 Mar 15. Clin Genitourin Cancer. 2014. PMID: 24787966 Free PMC article.

10

Phase II Study of Pazopanib and Paclitaxel in Patients With Refractory Urothelial Cancer.

Narayanan S, Lam A, Vaishampayan U, Harshman L, Fan A, Pachynski R, Poushnejad S, Haas D, Li S, Srinivas S. Narayanan S, et al. Among authors: harshman l. Clin Genitourin Cancer. 2016 Oct;14(5):432-437. doi: 10.1016/j.clgc.2016.03.011. Epub 2016 Mar 12. Clin Genitourin Cancer. 2016. PMID: 27068017 Free PMC article. Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

282 results

Search Page

Filters